Research programme: rheumatoid arthritis therapy - Deltagen

Drug Profile

Research programme: rheumatoid arthritis therapy - Deltagen

Alternative Names: Rheumatoid arthritis therapy research programme - Deltagen

Latest Information Update: 08 Mar 2011

Price : *
* Final gross price and currency may vary according to local VAT and billing address.

At a glance

  • Originator Deltagen
  • Class
  • Mechanism of Action Immunomodulators
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.


Highest Development Phases

  • Discontinued Inflammation; Rheumatoid arthritis

Most Recent Events

  • 01 Jul 2003 Deltagen has filed a voluntary petition under Chapter 11 of the federal Bankruptcy Code
  • 14 Oct 2002 Deltagen has discovered a new drug target for the potential treatment of rheumatoid arthritis
  • 22 Jul 2002 Preclinical trials in Inflammation in USA (unspecified route)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at so we can help.

Back to top